Logo Image
|Videos|May 12, 2017

Are Nurse-Driven Clostridium difficile Protocols Effective?

Gonzalo Bearman, MD, MPH, professor of medicine, and hospital epidemiologist, Department of Internal Medicine and Infectious Diseases, Virginia Commonwealth University, examines the importance of nurse-driven Clostridium difficile protocols.

Gonzalo Bearman, MD, MPH, professor of medicine, and hospital epidemiologist, Department of Internal Medicine and Infectious Diseases, Virginia Commonwealth University, examines the importance of nurse-driven Clostridium difficile protocols.

Interview Transcript (slightly modified for readability)

“Nurse-driven C. difficile protocols are really [an] unresolved issue in terms of whether we should or should not do them. We actually do them in my home institution.

The theory is that nurses, because they’re by the patients more than anyone else really, are the first to recognize a diarrheal syndrome. They should be given the latitude and freedom to order C. difficile tests within certain parameters to make an early diagnosis. By making an early diagnosis it leads to earlier treatment, earlier isolation, and potentially [could] decrease the risk of transmission to other patients.”

Related to this article

View more
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Read more
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Read more
ID Week Highlights Part 1
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
Read more